Dear ACT Colleagues,

Summer is here and we continue to plan for our 43rd Annual Meeting at the Gaylord Rocky Mountains outside Denver, Colorado, November 13 to 16, 2022. Registration is open, and we are very pleased with the number of anticipated attendees anxious to meet in person for our very exciting set of Continuing Education courses, Symposia, Workshops, and Plenary Lectures. All meeting details can be found on the ACT Annual Meeting website. Student travel awards, North American Travel Grants, and International Travel Grants are being reviewed now. Thanks to our Education and Program Committees for again putting together a great program.

While we are all looking forward to the Annual Meeting, ACT Council and committees have also been very active. Our members can see the results of these activities in the following highlights:

• The Toxicology for Pharmaceutical and Regulatory Scientists (March 2022) course was held virtually.
• The Pathology Course for Nonpathologists course was an in-person course held in Gaithersburg, Maryland, May 16–18.
• Registration for the Advanced Comprehensive Toxicology (August 1–5) course is open. This course will offer in-person attendance and a virtual component, with the option to purchase recordings as an add-on.
• The Practical Application of Toxicology in Drug Development course, co-hosted with the British Toxicology Society and Cambridge Alliance on Medicines Safety, will be a virtual course with Q&A sessions, taking place September 5–14. Registration is now open.
• ACT is strengthening our connections with international societies by:
  • Supporting $10,000 for student travel awards for the IUTOX 16th Congress of Toxicology to be held in Maastricht, Netherlands, September 18 to 21, 2022
  • Providing funding for IUTOX and the Turkish Society of Toxicology supporting a training course on Risk Assessment of Emerging and Legacy Toxicants for participants from the Balkans (countries such as Bosnia and Herzegovina, Serbia, Romania, Bulgaria, Ukraine, and Kosova), the Middle East (especially students from Iran, Jordan, Georgia, Azerbaijan, and Turkmenistan), and North Africa (especially those from Algeria, Tunisia, Morocco, and Egypt), May 23–28, 2022
  • Sponsoring Future Tox V-Organ Specific Toxicology: New Technologies to Evaluate Organ-Specific Effects of Drugs and Chemicals, to be held in Research Triangle Park, North Carolina, May 10 and 11, 2022
• A review of accomplishments supporting the first two years of our current three-year Strategic Plan was conducted in April, along with our first face-to-face Council meeting in over two years. The review of actions for the final year of our current plan along with recommendations for our next three-year Strategic Plan is in progress. Central to all our strategic planning continues to be how ACT can deliver excellent scientific education and advance professional development in the era of COVID and post-COVID.
• The Diversity, Equity, and Inclusion (DEI) Working Group was sunset, following their establishment of a page on our website that includes our DEI statement and submission of a series of recommendations. Some of the recommendations are already in place, and future recommendations will be instituted by various ACT committees. To ensure that DEI remains central to all that ACT does, the DEI Subcommittee, chaired by Peyton Myers and reporting into the Outreach Committee, has been established.
• Council approved the election ballot recommended by the Nominating Committee for ACT officers, Council, and committees. The committee, with the aid of the Leadership Development Working Group, worked diligently to identify a slate of diverse and qualified candidates.
  • The ballot is open until mid-August. Please be sure to cast your vote to select the next generation of ACT leaders. A special thanks to all the candidates who stepped up to serve the College!
• It’s time for you to signal your interest in joining an appointed committee for 2023, with terms beginning December 1, via the volunteer sign-up page of the website. ACT leadership will begin reviewing candidates later this summer. This is a great way to contribute to our organization and to actively engage with and befriend other professionals.

Finally, I need to thank all our members who continue to support ACT activities. Over 20% of our membership actively participates in committees and subcommittees, and approximately 50% of our members attend our Annual Meeting. We look forward to providing more value to our members and can do this only with your suggestions and continued support of the College, including our Annual Meeting, courses, webinars, podcasts, and eLearning series, as well as your generous support of our Endowment.

Enjoy your summer, and I hope to see you in the fall.

Embracing DEI (Diversity, Equity, and Inclusion) can have huge positive impact on the future of scientific societies that span many countries and cultures. ACT has embraced DEI through many actions and activities in the past (countless awards/grants for students from multiple countries, the Mildred Christian Women’s Leadership in Toxicology Award, etc.). Through the DEI Working Group and now the DEI Subcommittee, these DEI efforts at ACT have been organized and focused within the College.

One of the more visible examples of these efforts was the DEI Survey, which was used to set a baseline for DEI at ACT. Over 200 ACT members participated in the survey as well as the follow-up focus groups and interviews. Key survey outputs are summarized here.

Survey parameters:

• The survey was sent to approximately 1,000 individuals in ACT from July 5 to July 23, 2021, with an overall 21% response rate. Notably, this is considered an average rate for these types of surveys.
• Four one-hour focus groups as well as 1:1 interviews with key stakeholders were hosted to garner further feedback.

Most respondents felt that ACT embraces DEI in many aspects:

• 57% feel ACT’s structure encourages DEI.
• 74% agree that the organization supports success from all cultures/ backgrounds.
• 72% believe ACT takes appropriate action in response to incidents of discrimination.
• 76% feel ACT supports equitable sharing of knowledge, collaboration, and communication.
• 86% feel they can bring their authentic self to the organization.
• 74% believe that ACT helps facilitate a climate of inclusivity and belonging.
• 87% believe they have volunteer opportunities at ACT regardless of their identity.

The majority of respondents felt that selection for various positions in ACT is equitable, but the lower rates suggest that improvements can be made:

• 56% believe the selection of members for committees and professional development opportunities is fair and equal.
• 59% feel they are aware of the selection process for Council and committee members.
• 64% believe everyone is considered fairly for leadership/volunteer opportunities.

Lastly, the Annual Meeting (AM) location was queried for DEI concerns. Although the overall AM locations may have some DEI challenges per the responses, most respondents feel safe in the locations and would still attend the meeting:

• 53% feel active measures are taken in seeking a DEI-friendly location, and 40% were neutral.
• 81% feel safe in the locations selected.
• 89% disagree they have decided to NOT attend based on DEI concerns about location.

Although there were many positive aspects in the survey, there are always areas for improvement. The survey identified several areas to address. Some of these included:

• Better communicating DEI efforts with the ACT membership
• Enhancing understanding regarding the nomination processes as it relates to diversity
• Investigating issues related to recruiting and retaining younger members (including financial barriers to attending the ACT AM for younger scientist)

In short, the DEI Survey identified many positive indicators for ACT as well as some areas that could use enhancement. Some identified areas (such as removing financial barriers for younger scientists) have already resulted in changes voted in by Council. Other efforts will take more time and discussion to properly address. The DEI Subcommittee will work in concert with other committees to address these other identified areas that need enhancement.

Lastly, it cannot be stressed enough that the outcomes and DEI baseline information are a direct result of the feedback from the members via the survey. The DEI Subcommittee would like to thank all the members who took time to take the survey as well as volunteer their time for the various focus groups. It is with your help that we can advance DEI in ACT and better enhance ACT for the future of toxicology.

Recently, human cases of monkeypox have been identified in a number of countries, including the United Kingdom and the United States. Where this outbreak originated and how it is being transmitted is still a mystery.

Monkeypox is a zoonotic disease that has jumped from animals to humans a number of times. It is thought to originate in Central and Western Africa in rodents, but increased transmission in Africa may suggest that the virus is being spread by a new animal reservoir. Monkeypox typically spreads though close contact with an infected person via body fluids, and symptoms include fever, headache, aching limbs, fatigue, and a rash with blisters and pustules, similar to smallpox.

All current cases of monkeypox outside Africa are the West African clade, which results in a mild version of the disease that can resolve without treatment. There are no approved drugs for monkeypox; however, antivirals used to treat smallpox, including cidofovir, brincidofovir, and tecovirimat, can be used. In addition, approved vaccines for monkeypox and smallpox and antibodies from vaccinated people can be administered early in disease to mitigate symptom progression.

A lot is still unknown about the current transmission of monkeypox outside Africa. Extensive contact tracing and sequencing of the virus can provide some insight and potentially help manage the spread globally. Stay tuned!

Read more about the current status of monkeypox in Scientific American.

Gene therapies offer a unique opportunity to tackle or even cure rare diseases, but their development needs to be modernized. The Center for Biologics Evaluation and Research chief, Peter Marks, thinks that greater use of novel trial designs and endpoints, global regulatory harmonization, standardized manufacturing processes, and improved communication with regulators would have a big impact on getting more gene therapies to market.

Marks believes that sponsors should consider the use of surrogate endpoints, such as biomarkers that have been shown in nonclinical models to correlate well with therapeutic response, to demonstrate endpoints are statistically significant in small patient populations. Additionally, the use of Bayesian clinical trial designs that include reassessments of therapeutic benefit probability as each patient goes through the trial process can help lower the number of participants needed in gene therapy trials and the small pools of rare disease patients that can make enrollment a struggle.

Given the global divergence of regulatory frameworks for gene therapy, enhanced communication with regulators could alleviate challenges for developers of gene therapies both large and small. The US FDA offers expedited review programs as a part of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation. Additionally, Marks recommends sponsors take advantage of informal regulatory meetings, such as the INTERACT meetings at the Center for Biologics Evaluation and Research at the US FDA. In support of global regulatory harmonization, an ongoing effort is in progress through the World Health Organization.

Gene therapy manufacturing faces huge bottlenecks, especially in the manufacture of viral vectors. Marks says he envisions a suite of different vector backbones that would operate across the gene therapy industry. The concept of a reusable vector is part of a wider discussion Marks and others at the US FDA are having with industry about standardizing gene therapy production and regulation. This is taking place under a public-private partnership known as the Bespoke Gene Therapy Consortium.

oHCM is a rare disease that occurs when the heart muscle thickens, mostly in the septum (the heart wall that separates its right and left sides) and obstructs blood flow from the heart to the rest of the body. The severity of oHCM varies, but it can cause serious symptoms and death. Symptoms include palpitations (the sensation the heart is pounding), shortness of breath, swelling of the legs, and decreased exercise capacity, which significantly impact daily activities and quality of life.

Camzyos works by reducing contraction of the heart muscle, which can cause heart failure or totally block functioning of the ventricles (lower chambers of the heart). Patients who have a serious intercurrent illness (such as a serious infection) or arrhythmia (atrial fibrillation or other uncontrolled fast heart rhythm abnormality) are at greater risk of developing impaired heart muscle contraction and heart failure with Camzyos.

Because of the risk for heart failure, patients treated with Camzyos must be monitored with echocardiograms, an imaging test that shows how well the heart is working. Patients must also avoid certain prescription and over-the-counter medicines that interfere with the metabolism (breakdown) of Camzyos. At the end of March 2022, the FDA approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD. CDD is a rare developmental epileptic encephalopathy (dysfunction of the brain) caused by CDKL5 gene mutations. The CDKL5 gene is responsible for making proteins that are important for normal brain functioning and development. Patients with CDD typically have infantile-onset epilepsy that responds poorly to currently available treatments. Other symptoms include hypotonia (poor muscle tone), severe developmental and cognitive delays with little or no speech production, fine and gross motor impairment (including inability to walk for most patients), cortical visual impairment, behavioral abnormalities, and sleep and digestive difficulties. Although rare, the incidence of CDD is believed to be between 1 in 40,000–60,000 live births, making it one of the most common genetic forms of epilepsy.

Covid treatments continue to make good strides. April 2022 saw the FDA approve the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are:

• Hospitalized, or
• Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death

This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age. As a result, the agency also revoked the emergency use authorization for Veklury that previously covered this pediatric population.

Before now, Veklury was approved to treat only certain adults and pediatric patients (12 years of age and older who weigh at least 40 kilograms, which is about 88 pounds) with COVID-19.

To date, the FDA has approved two vaccines, and three vaccines are available for emergency use, to prevent COVID-19 and the serious clinical outcomes associated with COVID-19, including hospitalization and death.

In the UK, the MHRA has approved the COVID-19 vaccine developed by Valneva after a rigorous review as well as Evusheld (tixagevimab/cilgavimab) for COVID-19 prevention, after it had found that it had met the required safety, quality, and effectiveness standards.

Registration for the ACT 43rd Annual Meeting is open! Join us November 13–16, 2022, at the Gaylord Rockies, located outside Denver, Colorado.

The 43rd Annual Meeting will include a wide-ranging scientific program and educational courses with distinguished plenary speakers, the popular poster session, an awards ceremony, and several professional networking events.

The ACT Expo Live! and the ACT Annual Meeting Support program provides companies with a unique environment—toxicologists, industry consultants, and other professionals in one location with networking and marketing opportunities at every turn. We invite your company to join us as an exhibitor or supporter so that you can make professional connections and gain valuable exposure at the Annual Meeting.

Register Today!

 
Early-bird registration pricing ends September 19, 2022.

Visit the ACT 43rd Annual Meeting website to find more details about the 2022 event.

We look forward to seeing you in Denver, Colorado!

The mountains are calling you to the ACT 43rd Annual Meeting. ACT cannot wait to welcome you back to the Annual Meeting this November 13-16, returning full force with a schedule packed with premier scientific sessions and engaging networking opportunities. The host hotel, the Gaylord Rockies, is another addition to the long list of reasons to attend, showcasing Colorado’s alpine charm by welcoming guests with its beautiful Grand Lodge and stunning Rocky Mountain views. Breath-taking views and convenient location, you won’t want to be left out of the room block so book your housing reservations for the Annual Meeting now! Visit the Annual Meeting Housing page for detailed information on hotel policies, booking government housing or requesting student housing.

Housing Deadline: September 19
Room Rate: $250 per night/single or double occupancy

Book Now!

New this year for student members! A limited number of student-rated guest rooms for $169 are available in the headquarters hotel to registered ACT Student and Postdoctoral Members. Complete this form to request a student-rated guest room at the Gaylord Rockies. Notifications will go out in August as to the status of your request.

Guest room reservations at the Gaylord Rockies will be taken until the block is sold out or until the cutoff date of September 19, 2022, whichever comes first.

BUYER BEWARE of Possible Hotel Reservation Fraud

We have been made aware of unauthorized companies contacting ACT exhibitors and registrants offering hotel reservations at the ACT headquarters hotel. These “unofficial” housing companies are aggressively pursuing exhibitors and attendees to book hotel rooms through their company at supposedly significant discounts. Unfortunately, some past attendees have fallen prey to these companies and have been relocated with little or no warning, lost their significant deposits, not been given the type of guest rooms they thought they had booked, or not been given the hotel they thought they had booked. This has caused great hardships to these individuals.

ACT does not work with an official housing company. Please be sure to make your reservation directly with the hotel via phone or the housing links. Reservations made through anyone other than the hotel or their reservation center will be at your own risk. Please note that the Gaylord Rockies does not solicit reservations or credit card information by phone. If another housing company trying to sell hotel rooms contacts you, please notify ACT Headquarters.

The ACT Annual Meeting offers a unique, intimate environment unlike any other in the toxicology community. Because of the top-notch scientific programming and well-known, expert speakers who present the latest science, this meeting has earned a reputation among toxicologists worldwide for being the “must attend” event of the year. The size of the meeting is particularly well suited for in-depth peer-to-peer networking, as well as making B2B connections. Download the Annual Meeting Supporter Form for complete details, and contact Liz Kasabian with any questions at 703.547.0875 ext.1437.

The American College of Toxicology Sincerely Appreciates the Generous Contributions of Our Annual Meeting Supporters Thank You! as of June 9, 2022 Platinum $10,000+ Gold $5,000–$9,999   Silver $2,500–$4,999 Bronze $1,000–$2,499 Aclairo Biogen Eurofins Regulatory Science Services Gad Consulting Services Gilead Sciences Inc. MEC Regulatory & Toxicology Consulting, LLC Safety Pharmacology Society Sanofi U.S. SNBL Society of Toxicology Toxicology Solutions, Inc. ToxStrategies, Inc. Independent Consultant $300 Minimum EdGe Toxicology Consulting Ltd. River Bluff Associates, LLC Visit the ACT 43rd Annual Meeting Website To become an Annual Meeting Supporter plese contact Liz Kasabian, exhibits@actox.org

A valuable, year-round resource for toxicologists, at ACT Expo Live! you will find companies offering the latest in technology, equipment, and services for the toxicology community. More than 50 companies have already reserved a booth, but you don’t have to wait until November to connect with them—visit ACT Expo Live! today!

Interested in a booth at ACT Expo Live? The exhibit hall is already 80% sold, so reserve your booth today! Check out the competition—our current exhibitors know that this event provides exhibitors with a unique environment that cannot be found elsewhere—hundreds of toxicologists, research scientists, industry consultants, and other professionals in one location, with networking and marketing opportunities at every turn.

In addition to the scientific posters in the hall, there are coffee breaks, an evening social, a breakfast reception, and other special events that allow meeting attendees to have plenty of opportunities to visit the exhibition to discuss their needs and find solutions from trusted industry suppliers. The size of the meeting is especially conducive to intimate and relaxed interactions between meeting participants and exhibitors, and the perfect opportunity for making valuable B2B connections with other exhibiting companies. Request a booth today!

Questions? Contact Liz Kasabian for answers.

Starting this summer, we will be seeking session proposals for our 2023 Annual Meeting in Florida, and it is not too early to start thinking about it! What would be a topic that you would like to see addressed in a session? Do you have an idea for a session that you would be willing to present or chair? Member involvement in determining our Annual Meeting scientific program is an important tradition of our College. Start thinking about topics and be ready to support your 2023 program. The scientific program that we offer at our Annual Meeting is only as good as we collectively make it!

Stay tuned for details on upcoming brainstorming sessions in the summer, in the fall, and at the Annual Meeting, and consider submitting a proposal when our session proposal portal opens.

If you are an ACT speaker or planning a professional presentation and require guidance on how to ensure your materials are free of copyright infringement or legal ramifications, there are many resources available for your information on the interACT website.

From the home page, navigate to the “File Library” dropdown menu and select “SOPs and Reference Documents.” Resources can be found under the “References” menu at “Copyright for ACT Speakers.” On this page, you will find links to a speaker resource packet and a 36-minute video presented by a copyright attorney. The packet contains valuable information on what is and is not protected by copyright, links to help obtain copyright permission, and guidance on how to use trademarks. This interACT page is a convenient one-stop shop for ACT speakers, as there are also links to the ACT speaker licensing agreement form, the supplemental speaker agreement form, expense guidelines, and ACT slide templates. Review these great resources before your next planned speaking engagement.

1. What company do you currently work with, what is your profession, and how long have you been a member of ACT?
I’m currently a PhD candidate going into my fifth year in the Molecular Toxicology Program at UCLA. I’ve been a member of ACT since 2019.

2. What is your favorite part of being a member of ACT?
What I love about ACT is the constant exchange of ideas and how the entire community is committed to helping each other succeed. Conversations with other ACT members have given me great ideas or opportunities to pursue. I recently joined the Early Career Professionals Subcommittee and I’m excited about the things we’re going to accomplish and the difference we’ll make. It’s really motivating to work with such a great community of scientists.

3. Who has been the most influential person in your career?
My PhD mentor, Dr. Elissa Hallem. She is incredibly passionate about science and public health and asking the hard questions that no one else is trying to answer. She has been influential in changing how I view challenges in my career and in learning how to adapt and benefit from any experience. I’ve gained a greater understanding in being both cautious in and focused on the way I approach science, as well as optimistic that what I find out will be remarkable. She’s also influenced me to reflect on my science and be able to consider every perspective, idea, and possibility in my research, and by extension, how I progress in my career to find the most impactful answers.

4. When you were growing up, what did you want to be?
I wanted to be a scientist from a very young age. I asked so many questions as a kid, that one day my mom bought me these books that talked about things like how the leaves change color. After learning about science for the first time, I was addicted to learning more. I grew up and knew that I was never going to stop wanting to learn and ask and answer questions about the world, so I should just go ahead and make a career out of it.

5. Name three secret steps to career success.

1. Set aside time, outside of your normal workday, to think of (what may seem like) crazy ideas. Let yourself dream about science.
2. Take advantage of every opportunity—even if you think there is only a small chance you’ll get it, take it anyway.
3. Find your support system and use it. Be willing to ask for help from your mentors.

The Membership Committee recommended membership to 28 new applicants in various membership categories. We would like to extend a very warm welcome to the new members!

New ACT Members—June 2022:

ACT Corporate members provide a sustained and important contribution to our success with their financial contributions, helping ACT pursue key strategic initiatives and deliver timely educational programs.
To learn more about our Corporate members, click on their links below.

A sincere “Thank You!” to our Corporate Members for their generous support and dedication to ACT.

(As of June 28, 2022)

Corporate Partners

The International Journal of Toxicology Editorial Board and ad hoc reviewers have been busy, not only with manuscript reviews, but also with some other important tasks. At the time of preparing this message, we are on par with submission numbers over the past two years, so we’ve got a lot of reviewing in progress! In addition, I invited several members of the Editorial Board to participate in the selection of the Best Paper Published in International Journal of Toxicology in 2021. In selecting the papers for this award, we look for papers that address a contemporary issue(s) in toxicology; that show an immediate positive impact as measured by citations, downloads, and Altmetric scores; and that have the potential to have a broad and long-lasting impact on the field or practice of toxicology. Thanks to Drs. Sandy Eldridge, Erica Carroll, and Charleata Carter for working on this year's selection. We’ll announce the results at a later date.

In terms of other activities, readers of International Journal of Toxicology may have noticed that we publish the ACT Policy Statement on the Use of Animals in Toxicology at least once per year. You may also have noticed the disclosure that the policy was last revised in 2001. I received support from the ACT Executive Council to convene a committee to review the policy and revise, if necessary. I extend my sincere thanks to Drs. Noel Horton, Daniel Patrick, Suzanne Wolford, and Scott Williams for their time and wisdom in reviewing and providing small but important modifications. Look for the Policy Statement for a second time in 2022 in an upcoming issue.

Finally—we’re eagerly awaiting our updated impact factor. Preliminary indicators are that we are expecting a slight increase again this year. Fingers are crossed that I’ll be able to confirm this in our next newsletter!

Hello from the Education Committee, and happy halfway through the year!

As we head into the hazy days of summer, there is nothing lazy about the activities of the Education Committee (EdCom). In a few short months we will be gathering in Denver for our face-to-face 2022 Annual Meeting. The EdCom has generated an exciting Continuing Education (CE) curriculum for this year’s Annual Meeting, so please go and register and join us for one of the excellent CE courses. Note that we are trying to provide more interactive and case-based courses, as you requested. Here is a quick list of the CE courses. With so many great choices, it will be hard to choose!

• Full-day interactive course: Strategies for a Successful Nonclinical Study: Study Director and Monitor Training
• Identifying and Understanding Seizure Liability in Pharmaceutical Development
• WOE: Is an Animal Study Warranted? Assessments for Carcinogenicity, Drug Abuse Liability, and Pediatric Safety
• Applications of Artificial Intelligence and Machine Learning in Toxicologic Pathology
  • In collaboration with the Society of Toxicologic Pathology
• Interactive Session on the Challenges of Species Selection across Classic and Novel Modalities
• How to Complete an Extractable or Leachable (E/L) Risk Assessment When the Unexpected Happens: A Workshop to Provide Available Approaches Using Case Studies Related to Medical Devices or Medical Device Combination Products
• Product Quality Strategies and Occupational Toxicology Best Practices for Project Toxicologists Tasked with DOING IT ALL!

In the second half of the year, the EdCom will be focusing on the long-range strategic plan and how to bring more educational value to your membership. We are working to identify opportunities for online learning, as well as enhanced opportunities for face-to-face programs. Like most things, it will take a village to help guide our ongoing enhancements and bring the right kind of educational opportunities to ACT at the right time. So, watch for requests to let us know what you want, and if interested, please join us and get involved. In the meantime, enjoy the summer, and we are all looking forward to being back together in November.

The ACT Advanced Comprehensive Course will be offered in a hybrid format in 2022! For the same price, registrants may participate in the course in person at the Marriott Washingtonian in Gaithersburg, Maryland, US, from August 1 to August 5, 2022, or via remote access. Advantages of participating in person include a networking reception, opportunities to directly interact with course speakers, and breakfast and lunch each day. Those taking the course remotely will have real-time access to speaker presentations, and, together with the in-person participants, the opportunity to participate in an open Q&A session on the last day of the course. All course participants will have the option to purchase recordings of the lectures and will have access to a practice exam that is consistent in format with the American Board of Toxicology’s certification exam.

So, what are you waiting for? Check out the registration details for the ACT Advanced Comprehensive Course on the ACT website. We look forward to seeing you in Gaithersburg (or online!) in August!

• ToxChats Podcast: Moving from Minion to Manager
• New ToxChats Podcast: Tips for Taking the ABT Exam

The SOT Medical Device and Combination Product Specialty Section and Computational Toxicology Specialty Section have organized a webinar titled "Integrating Mass Spectrometry Non-Targeted Analysis and Computational Toxicology to Characterize Chemicals."

• Date: June 30, 2022
• Time: 11:00 AM–12:00 Noon Eastern Time (US and Canada)

Registration and more information are available on the SOT website.

The live session of this webinar will have been completed by the time this article is read in the newsletter. However, the recorded presentation will be available for review online within two days of the live event.